BURNABY, British Columbia, September 16th, 2020 – Symvivo Corporation today announced the appointment of Lloyd Mackenzie as the company’s President and Chief Operating Officer.
Mr. Mackenzie is a biotechnology Research and Development executive with over 25 years of experience in drug development, manufacturing and control, quality assurance, clinical development and clinical operations. Mr. Mackenzie was formerly the Chief Operating Officer at Nervgen Pharma, with prior executive level experience at Notable Labs and Aquinox Pharmaceuticals.
“The addition of Lloyd’s leadership, strategic insight and operational experience in all aspects of therapeutic development is critical step in the development of Symvivo, enabling us to drive our therapeutic programs deeper in the clinic while broadening the application of the bacTRL gene delivery platform,” said Alexander Graves, Chief Executive Officer of Symvivo Corporation. “We’re delighted to have him join the Symvivo team.”
Symvivo is a clinical stage biotechnology company advancing a proprietary platform for the site- specific delivery of genes for the treatment and prevention of disease. Symvivo’s bacTRL platform technology delivers plasmid DNA, both orally and through IV application, that enables a patient’s own cells to produce therapeutic proteins. Symvivo is advancing therapeutics in the area of oral DNA vaccines, oncology, immunology and gene replacement. Symvivo is headquartered in Burnaby BC. For more information visit www.Symvivo.com
Sam Brown Inc. Healthcare Communications
T: 613-319-4384 (CAN)
T: 805-242-3080 (U.S.)